)
Christopher Roth
Vice President of Research,
Abilita Therapeutics, Inc.
Christopher Roth, PhD is the Vice President of Research at Abilita Therapeutics, where he is leading multiple therapeutic antibody discovery programs targeting GPCRs and ion channels for the treatment of cancer and pain. Prior to joining Abilita, Chris was a member of the founding scientific team at Receptos, where he invented novel GPCR engineering technologies that underpinned the structure-based discovery platform. Chris earned his PhD in the laboratory of Ray Stevens at The Scripps Research Institute, where he was a member of the team that solved seminal high-resolution GPCR crystal structures and developed core approaches used throughout the field today.